Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.…
Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics Corp (NASDAQ: SLXN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 1.310 USD on 20 November 2026, down 99.8% over 52 weeks. Its 52-week range is 1.260 USD to 804.00 USD: the price is 99.8% below the high and 4.0% above the low.
Its market capitalisation is 850.88K USD.
Silexion Therapeutics Corp reports return on equity of -457.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 819.00K USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.